Table 3.
Antimicrobial susceptibility of Salmonella and Shigella isolated from human gastrointestinal infections in Shanghai, 2006–2012
| Antimicrobials | Salmonella | Shigella* | ||||
|---|---|---|---|---|---|---|
| S. Enteritidis (n = 1550) | S. Typhimurium (n = 1174) | All Salmonella (n = 4483) | S. sonnei (n = 1248) | S. flexneri (n = 473) | All Shigella (n = 1724) | |
| Amoxicllin | 4·4 | 12·6 | 7·1 | 1 | 64·7 | 18·4 |
| Ampicillin | 59·7 | 55·7 | 41·6 | 84·2 | 95·5 | 87·2 |
| Cefepime | 4·8 | 5·1 | 4·0 | 13·5 | 15·4 | 14·0 |
| Cefotaxime | 7·4 | 9·7 | 7·0 | 27·9 | 30·7 | 28·6 |
| Ceftazidime | 3·7 | 7·0 | 5·0 | 9·6 | 12·5 | 10·4 |
| Ceftiofur | 2·7 | 4·7 | 3·4 | n.t. | n.t. | n.t. |
| Chloramphenicol | 4·1 | 41·1 | 17·8 | 1·6 | 92·4 | 26·5 |
| Ciprofloxacin | 5·4 | 21·0 | 10·7 | 1·4 | 37·6 | 11·4 |
| Gentamicin | 11·7 | 31·6 | 15·0 | 73·8 | 10·4 | 56·3 |
| Nalidixic acid | 96·0 | 66·0 | 57·9 | 97·7 | 97·0 | 97·5 |
| Ofloxacin | 0·6 | 1·7 | 1·4 | 0·6 | 32·4 | 9·3 |
| Streptomycin | 48·0 | 65·8 | 47·6 | 97·9 | 97·9 | 97·7 |
| Sulfonamides | 60·9 | 68·3 | 59·2 | 77·5 | 61·1 | 72·9 |
| Tetracycline | 26·9 | 55·1 | 29·3 | 73·5 | 95·5 | 79·4 |
| Trimethoprim | 9·3 | 40·1 | 21·0 | 98·4 | 97·7 | 98·1 |
| Trimethoprim + sulfamethoxazole | 9·5 | 41·3 | 21·1 | 85·1 | 63·2 | 78·9 |
n.t., Not tested.
*
Shigella isolated from 2008 to 2012 were tested for antimicrobial susceptibility.
Values given are percentages.